C4 Therapeutics, Inc. (CCCC)
Automate Your Wheel Strategy on CCCC
With Tiblio's Option Bot, you can configure your own wheel strategy including CCCC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CCCC
- Rev/Share 0.5616
- Book/Share 2.7549
- PB 0.5336
- Debt/Equity 0.3298
- CurrentRatio 5.6966
- ROIC -0.3937
- MktCap 104380437.0
- FreeCF/Share -1.1365
- PFCF -1.2966
- PE -1.0082
- Debt/Assets 0.2014
- DivYield 0
- ROE -0.4586
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CCCC | Wells Fargo | Equal Weight | Overweight | $8 | $12 | Dec. 19, 2024 |
News
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.41 per share a year ago.
Read More
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g, Including One Patient With a Minimal Residual Disease Negative Complete Response ; 40% ORR Achieved at the 75 µ g Dose Level
Read More
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026
Read More
C4 Therapeutics to Participate in Upcoming March Investor Conferences
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences.
Read More
About C4 Therapeutics, Inc. (CCCC)
- IPO Date 2020-10-02
- Website https://www.c4therapeutics.com
- Industry Biotechnology
- CEO Mr. Andrew J. Hirsch M.B.A.
- Employees 110